Logo

Tempus

In Brief This Week: Quidel, Ortho Clinical Diagnostics, Hologic, Guardant Health, and More

News items for the in vitro diagnostics industry for the week of Feb. 1, 2021.

Tempus, A2 Biotherapeutics Partner to Develop CDx for Therapy Targeting Loss of Heterozygosity

Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.

JP Morgan Healthcare Conference 2021, Day One: Roche, Guardant, Hologic, Thermo Fisher, and More

Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay. 

Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer

The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.

Tempus Gets CE Mark for xT Tumor Sequencing Assay

The xT platform integrates structured clinical patient data with results from a 648-gene DNA panel and whole-transcriptome RNA sequencing.